Antibody-Drug Conjugates (ADCs) for Personalized Treatment of Solid Tumors: A Review.

Published on Mar 30, 2017in Advances in Therapy3.871
· DOI :10.1007/S12325-017-0519-6
John M. Lambert52
Estimated H-index: 52
(ImmunoGen, Inc.),
Charles Q. Morris1
Estimated H-index: 1
(ImmunoGen, Inc.)
Sources
Abstract
Attaching a cytotoxic “payload” to an antibody to form an antibody–drug conjugate (ADC) provides a mechanism for selective delivery of the cytotoxic agent to cancer cells via the specific binding of the antibody to cancer-selective cell surface molecules. The first ADC to receive marketing authorization was gemtuzumab ozogamicin, which comprises an anti-CD33 antibody conjugated to a highly potent DNA-targeting antibiotic, calicheamicin, approved in 2000 for treating acute myeloid leukemia. It was withdrawn from the US market in 2010 following an unsuccessful confirmatory trial. The development of two classes of highly potent microtubule-disrupting agents, maytansinoids and auristatins, as payloads for ADCs resulted in approval of brentuximab vedotin in 2011 for treating Hodgkin lymphoma and anaplastic large cell lymphoma, and approval of ado-trastuzumab emtansine in 2013 for treating HER2-positive breast cancer. Their success stimulated much research into the ADC approach, with >60 ADCs currently in clinical evaluation, mostly targeting solid tumors. Five ADCs have advanced into pivotal clinical trials for treating various solid tumors—platinum-resistant ovarian cancer, mesothelioma, triple-negative breast cancer, glioblastoma, and small cell lung cancer. The level of target expression is a key parameter in predicting the likelihood of patient benefit for all these ADCs, as well as for the approved compound, ado-trastuzumab emtansine. The development of a patient selection strategy linked to target expression on the tumor is thus critically important for identifying the population appropriate for receiving treatment.
Figures & Tables
Download
📖 Papers frequently viewed together
726 Citations
1,963 Citations
537 Citations
References96
Newest
#1Kathleen N. Moore (University of Oklahoma Health Sciences Center)H-Index: 44
#2Lainie P. Martin (Fox Chase Cancer Center)H-Index: 28
Last. Michael J. Birrer (Sarah Cannon Research Institute)H-Index: 109
view all 9 authors...
PurposeThis phase I expansion cohort study evaluated the safety and clinical activity of mirvetuximab soravtansine (IMGN853), an antibody–drug conjugate consisting of a humanized anti–folate receptor alpha (FRα) monoclonal antibody linked to the tubulin-disrupting maytansinoid DM4, in a population of patients with FRα-positive and platinum-resistant ovarian cancer.Patients and MethodsPatients with platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer received IMGN85...
71 CitationsSource
#1Edith A. Perez (Mayo Clinic)H-Index: 98
#2Carlos H. Barrios (PUCRS: Pontifícia Universidade Católica do Rio Grande do Sul)H-Index: 56
Last. Paul Ellis (Guy's and St Thomas' NHS Foundation Trust)H-Index: 6
view all 15 authors...
PurposeTrastuzumab and pertuzumab are human epidermal growth factor receptor 2 (HER2) –targeted monoclonal antibodies, and trastuzumab emtansine (T-DM1) is an antibody–drug conjugate that combines the properties of trastuzumab with the cytotoxic activity of DM1. T-DM1 demonstrated encouraging efficacy and safety in a phase II study of patients with previously untreated HER2-positive metastatic breast cancer. Combination T-DM1 and pertuzumab showed synergistic activity in cell culture models and ...
167 CitationsSource
#1John M. Lambert (ImmunoGen, Inc.)H-Index: 52
7 CitationsSource
8 CitationsSource
#1Raffit HassanH-Index: 58
#2John NemunaitisH-Index: 79
Last. Barrett H. Childs (Bayer AG: Bayer HealthCare Pharmaceuticals)H-Index: 27
view all 16 authors...
Background: Mesothelioma is a rare but aggressive cancer with a 5-year survival rate less than 10%. Mesothelin is a protein normally present on mesothelial cells and overexpressed in the majority of mesotheliomas. Anetumab ravtansine (BAY 94-9343) is a novel fully human anti-mesothelin IgG1 antibody conjugated to ravtansine, an antitubulin cytotoxic agent. In a phase I study, anetumab ravtansine at 6.5 mg/kg on a q3w IV schedule was well tolerated and showed encouraging durable tumor responses i...
1 CitationsSource
#1Hagop M. Kantarjian (University of Texas MD Anderson Cancer Center)H-Index: 234
#2Daniel J. DeAngelo (Harvard University)H-Index: 82
Last. Anjali S. Advani (Case Western Reserve University)H-Index: 35
view all 14 authors...
BackgroundThe prognosis for adults with relapsed acute lymphoblastic leukemia is poor. We sought to determine whether inotuzumab ozogamicin, an anti-CD22 antibody conjugated to calicheamicin, results in better outcomes in patients with relapsed or refractory acute lymphoblastic leukemia than does standard therapy. MethodsIn this phase 3 trial, we randomly assigned adults with relapsed or refractory acute lymphoblastic leukemia to receive either inotuzumab ozogamicin (inotuzumab ozogamicin group)...
539 CitationsSource
#1Rajeeva Singh (ImmunoGen, Inc.)H-Index: 23
#2Yulius Setiady (ImmunoGen, Inc.)H-Index: 15
Last. Wayne C. Widdison (ImmunoGen, Inc.)H-Index: 15
view all 22 authors...
A triglycyl peptide linker (CX) was designed for use in antibody-drug conjugates (ADCs), aiming to provide efficient release and lysosomal efflux of cytotoxic catabolites within targeted cancer cells. ADCs comprising anti-epithelial cell adhesion molecule (anti-EpCAM) and anti-epidermal growth factor receptor (anti-EGFR) antibodies with maytansinoid payloads were prepared using CX or a non-cleavable SMCC linker (CX and SMCC ADCs). The in vitro cytotoxic activities of CX and SMCC ADCs were simila...
15 CitationsSource
#1Bart De Goeij (Genmab)H-Index: 7
#2John M. Lambert (ImmunoGen, Inc.)H-Index: 52
The clinical success of Adcetris ® (brentuximab vedotin) and Kadcyla ® (ado-trastuzumab emtansine) has sparked clinical development of novel ADCs. These powerful anti-cancer agents are designed to allow specific targeting of highly potent cytotoxic agents to tumor cells while sparing healthy tissues. Despite the use of tumor-specific antibodies, the emerging clinical data with ADCs indicates that adverse effects frequently occur before ADCs have reached their optimal therapeutic dose, resulting ...
154 CitationsSource
#1Carlos Gomez-RocaH-Index: 24
#2Valentina BoniH-Index: 21
Last. Anthony W. TolcherH-Index: 72
view all 12 authors...
2511Background: SAR566658 (SAR) is a maytansinoid-loaded ADC targeting CA6, a sialoglycotope of MUC-1 over-expressed in solid tumors and rarely in normal tissues. Methods: Phase I dose escalation and expansion study to evaluate SAR intravenous administration as single agent every 3 weeks (q3w) and 2 weeks (q2w). Primary objective included dose limiting toxicities (DLTs), maximum tolerated dose (MTD) and recommended dose (RD). Secondary objectives were PK, PD and preliminary efficacy assessment (...
18 CitationsSource
#1Martin J. van den Bent (EUR: Erasmus University Rotterdam)H-Index: 96
#2Hui K GanH-Index: 34
Last. David A. Reardon (Harvard University)H-Index: 105
view all 20 authors...
2542Background: Recurrent GBM (rGBM) has dismal prognosis. Almost 50% GBM tumors harbor amplified (amp) EGFR. ABT-414 is a tumor specific ADC combining an antibody targeting a unique conformation of EGFR (ABT-806) to a microtubule cytotoxin, monomethyl auristatin F (MMAF). Here we report the safety and efficacy of ABT-414 monotherapy at recommended phase 2 dose (RPTD) in EGFR amp, rGBM. Methods: M12-356 (NCT01800695) is an open-label, phase 1, 3-arm study: Arm A (ABT-414+radiation/temozolomide (...
7 CitationsSource
Cited By130
Newest
#1Wenqian Li (JLU: Jilin University)H-Index: 4
#2Hanfei Guo (JLU: Jilin University)H-Index: 1
Last. Jiuwei Cui (JLU: Jilin University)H-Index: 29
view all 0 authors...
Introduction null Traditional cancer therapy has many disadvantages such as low selectivity and high toxicity of chemotherapy, as well as insufficient efficacy of targeted therapy. To enhance the cytotoxic effect and targeting ability, while reducing the toxicity of antitumor drugs, an antibody drug conjugate (ADC) was developed to deliver small molecular cytotoxic payloads directly to tumor cells by binding to specific antibodies via linkers. null Method null By reviewing published literature a...
Source
#1Aram J. Abbas (Damascus University)
Last. Maher S. Saifo (Damascus University)H-Index: 1
view all 0 authors...
The prognosis of breast cancer has radically changed in recent years and continues to improve due to the broad application of effective therapies. New targeting strategies including targeted delivery of cytotoxic drugs via receptor-targeting agents have been developed. We summarize recent publications and developments of novel antibody-drug conjugates (ADCs) used to control breast cancer.
Source
Antibody-drug conjugates (ADCs) are biopharmaceutical products where a monoclonal antibody is linked to a biologically active drug (a small molecule) forming a conjugate. Since the approval of first ADC (Gemtuzumab ozogamicin (trade name: Mylotarg)) for the treatment of CD33-positive acute myelogenous leukemia, several ADCs have been developed for the treatment of cancer. The goal of an ADC as a cancer agent is to release the cytotoxic drug to kill the tumor cells without harming the normal or h...
Source
#1Marion Chomet (VU: VU University Amsterdam)H-Index: 2
#2Guus A.M.S. van Dongen (VU: VU University Amsterdam)H-Index: 64
Last. Danielle J. Vugts (VU: VU University Amsterdam)H-Index: 33
view all 3 authors...
Inert and stable radiolabeling of monoclonal antibodies (mAb), antibody fragments, or antibody mimetics with radiometals is a prerequisite for immuno-PET. While radiolabeling is preferably fast, mild, efficient, and reproducible, especially when applied for human use in a current Good Manufacturing Practice compliant way, it is crucial that the obtained radioimmunoconjugate is stable and shows preserved immunoreactivity and in vivo behavior. Radiometals and chelators have extensively been evalua...
1 CitationsSource
#1Zhang ShuyongH-Index: 1
#2Dongdong ZhouH-Index: 1
Last. Zheng DexianH-Index: 1
view all 6 authors...
Abstract Acute lymphoblastic leukemia (ALL) is an aggressive hematological neoplasm resulting from immature lymphoid precursors. Antibody drug conjugate (ADC), coupling small molecule covalently with a targeting antibody, can specifically kill the tumor cells. Death receptor 5 (DR5) is considered as a promising anti-tumor drug target. Here, we describe the preclinical evaluation of a novel DR5-targeting ADC (Oba01) as a potential therapeutic against ALL. Oba01 utilizes anti-DR5 humanized monoclo...
Source
#1David Bussing (UB: University at Buffalo)H-Index: 2
#2Sharad Sharma (UB: University at Buffalo)H-Index: 7
Last. Dhaval K. Shah (UB: University at Buffalo)H-Index: 18
view all 5 authors...
Antibody-drug conjugates (ADCs) rely on high expression of target antigens on cancer cells to effectively enter the cell and release a cytotoxic payload. Previous studies have shown that ADC efficacy is not always tied to antigen expression. However, our recent in vitro study suggests a linear relationship between antigen expression and the intracellular levels of the ADC payload. In this study, we have explored the relationship between antigen expression and intratumoral ADC exposure in vivo. U...
Source
#1Jinghui Zhang ('SMMU': Second Military Medical University)H-Index: 1
#2Jiajun Fan (Fudan University)H-Index: 22
Last. Kai Yin ('SMMU': Second Military Medical University)H-Index: 5
view all 12 authors...
Trastuzumab emtansine (T-DM1), an antibody-drug conjugate consisted of the HER2-targeted monoclonal antibody trastuzumab and the tubulin inhibitor emtansine, has shown potent therapeutic value in HER2-positive breast cancer (BC). However, a clinical trial indicated that T-DM1 exerts a limited effect on HER2-positive gastric cancer (GC), but the underlying mechanism is inconclusive. Our research attempted to reveal the probable mechanism and role of autophagy in T-DM1-treated HER2-positive GC. In...
Source
#1Yangbing JinH-Index: 1
Last. Qian ZhanH-Index: 1
view all 10 authors...
Pancreatic ductal adenocarcinoma (PDAC) is the fourth leading cause of cancer-associated death in the United States and has a 5-year survival rate of <4%. Although much effort has been invested in the research and development of pancreatic cancer drugs over the past 30 years, due to the lack of effective targetable carcinogenic drivers, no new targeted therapies that can improve patient prognosis have been approved for clinical use. SHR-A1403 is a new c-mesenchymal-epithelial transition factor (...
Source
Target selection for antibody-drug conjugates (ADCs) frequently focuses on identifying antigens with differential expression in tumor and normal tissue, to mitigate the risk of on-target toxicity. However, this strategy restricts the possible target space. SLC34A2/NaPi2b is a sodium phosphate transporter expressed in a variety of human tumors including lung and ovarian carcinoma, as well as the normal tissues from which these tumors arise. Previous clinical trials with a NaPi2b targeting MMAE-AD...
1 CitationsSource
Bioconjugation has allowed scientists to combine multiple functional elements into one biological or biochemical unit. This assembly can result in the production of constructs that are targeted to a specific site or cell type in order to enhance the response to, or activity of, the conjugated moiety. In the case of cancer treatments, selectively targeting chemotherapies to the cells of interest limit harmful side effects and enhance efficacy. Targeting through conjugation is also advantageous in...
Source